# Safety and Pharmacokinetics of HU6

> **NCT05433506** · PHASE1 · COMPLETED · sponsor: **Rivus Pharmaceuticals, Inc.** · enrollment: 30 (actual)

## Conditions studied

- Obese

## Interventions

- **DRUG:** HU6 Tablet
- **DRUG:** HU6 Capsule

## Key facts

- **NCT ID:** NCT05433506
- **Lead sponsor:** Rivus Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-09-15
- **Primary completion:** 2023-01-30
- **Final completion:** 2023-03-15
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2023-03-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05433506

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05433506, "Safety and Pharmacokinetics of HU6". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT05433506. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*